In addition, patients with unexplained RECQL mutations were more likely to occur in patients with HER2+ cancer than those with other groups (p = 0.037), suggesting that unexplained RECQL mutations were more common in patients with HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.